Estados Unidos · Plataformas y datos · MarketBeat

Kymera Therapeutics (NASDAQ:KYMR) Stock Price Target Raised at Morgan Stanley

Publicado por MarketBeat · Estados Unidos hace 59 min

Morgan Stanley increased their price objective on Kymera Therapeutics from $135.00 to $146.00 and gave the stock an "overweight" rating in a research report on Tuesday.

Leer el artículo completo en MarketBeat Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.marketbeat.com)

Kymera Therapeutics (NASDAQ:KYMR) Stock Price Target Raised at Morgan Stanley

También te puede interesar

Here's How Much a $10,000 Investment in Realty Income Will Get You in Monthly Dividends

My wife cried when I found out she had only $80,000 in her 401(k). I have $2.2 million. Am I wrong to be shocked?

Best Stocks Under $5

Novartis Raises Guidance After Trial Setbacks Hit Profit

Walmart copies a core Costco move that also benefits customers

ATOSS Software Q3 2026 Earnings Call Is Live

Kymera Therapeutics (NASDAQ:KYMR) Stock Price Target Raised at Morgan Stanley

Compartir

También te puede interesar

Here's How Much a $10,000 Investment in Realty Income Will Get You in Monthly Dividends

My wife cried when I found out she had only $80,000 in her 401(k). I have $2.2 million. Am I wrong to be shocked?

Best Stocks Under $5

Novartis Raises Guidance After Trial Setbacks Hit Profit

Walmart copies a core Costco move that also benefits customers

ATOSS Software Q3 2026 Earnings Call Is Live